The hot topic at eyeforpharma in Barcelona 2019 is how to tackle non-adherence, and one of the main talking points will be whether behavioral science can crack non-adherence.
The premise is whether psychology and behavioral science, in particular — which looks at how people’s actions, emotions and thoughts — can be used to improve outcomes for patients and the healthcare system. Studies spanning long-term conditions show that non-adherence is related to doubts about personal need for the treatment and concerns about the potential adverse consequences of using it as advised.
In simple terms, it is explained that a patient’s motivation to start and continue with a prescribed medication is influenced by the way in which they judge their personal need for the medication (necessity beliefs), relative to their concerns about potential adverse effects.
Reaching out to patients with technology is now seen as the best way to alter behaviors and change outcomes. Curaizon, a UK-based healthcare technology company is working with this in mind.
On the patient side, its solutions issue non-intrusive reminders to patients so that they take medication on time, and as prescribed. From here, its medicine adherence technologies utilize AI, machine learning and big data to develop unique, standardized and anonymized datasets that medical researchers and pharmaceutical companies can easily use.
These enhanced and standardized data analysis tools can be effective in areas such as predictive medicine, patient relationship management, management of healthcare and measuring the effectiveness of certain treatments. Use of these new technologies will place a greater emphasis on preventive health solutions and patient-centric care.
Through its data analytics tools, Curaizon’s solutions aim to improve the quality and availability of real-time information. Its platforms will generate datasets on adherence based on anonymized big data using its technologies to facilitate end-to-end data integration, collaboration between different players in the healthcare sector, predictive modeling of the efficiency of different drugs to enhance clinical trial efficiency.
The real-time data and information gathered will then help caregivers channel the right messages to the right patients and deliver personalized care. This patient-centered approach ensures that patients get the right care for their individual characteristics, needs, preferences, and circumstances as they are actively involved in the treatment process — enabling optimal care delivery.
This data is stored off-chain onto an AES 256 encrypted cloud in an appropriate geographic domain with the blockchain storing pointers and rules on access and usage, all of which becomes part of the CuraData™ ecosystem. This ensures the security, transparency and immutability of medical records as access is restricted by the respective rules and storing points on the ecosystem.
The only way big pharma and medical researchers can access Curaizon’s invaluable patient data is by participating in its ICO this September by purchasing CuraTokens (CTKN). For more information, visit www.curatoken.curaizon.com.